This company is no longer active
Diffusion Pharmaceuticals Management
Management criteria checks 3/4
Diffusion Pharmaceuticals' CEO is Bob Cobuzzi, appointed in Sep 2020, they has a tenure of 2.92 years. Their total yearly compensation is $691.79K , comprised of 65% salary and 35% bonuses, including company stock and options. They directly owns 0.079% of the company’s shares, worth $10.66K. The average tenure of the management team and the board of directors is 4.9 years and 1.8 years respectively.
Key information
Bob Cobuzzi
Chief executive officer
US$691.8k
Total compensation
| CEO salary percentage | 65.0% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.9yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02
Aug 12We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully
Feb 25
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth
Nov 12We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate
Jun 25Diffusion Pharmaceuticals EPS misses by $0.02
May 10We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | US$692k | US$450k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$783k | US$410k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$1m | US$129k | -US$16m |
Compensation vs Market: Bob's total compensation ($USD691.79K) is about average for companies of similar size in the US market ($USD762.43K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Cobuzzi (58 yo)
2.9yrs
Tenure
US$691,787
Compensation
Dr. Robert J. Cobuzzi, Jr., also known as Bob, Ph D., serves as its President & Chief Executive Officer at Diffusion Pharmaceuticals Inc. since September 8, 2020 served as its Independent Director since Ja...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 2.9yrs | US$691.79k | 0.079% $ 10.7k | |
| General Counsel & Corporate Secretary | 2.9yrs | US$413.92k | 0.020% $ 2.6k | |
| Senior Medical Advisor | 10.9yrs | no data | no data | |
| Vice President of Clinical Operations | 6.9yrs | no data | no data | |
| Senior Consultant for Manufacturing | no data | no data | no data | |
| Senior Consultant - Regulatory Affairs | no data | no data | no data |
4.9yrs
Average Tenure
58yo
Average Age
Experienced Management: DFFN's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.6yrs | US$59.00k | 0.0016% $ 218.1 | |
| Independent Chairman | 2.9yrs | US$77.50k | 0.060% $ 8.1k | |
| Lead Independent Director | 7.6yrs | US$55.50k | 0.053% $ 7.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.6yrs | US$54.00k | 0.0035% $ 468.6 | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Independent Director | 2.2yrs | US$49.00k | 0.014% $ 1.9k | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.8yrs
Average Tenure
61yo
Average Age
Experienced Board: DFFN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.